Suche klinische Studie
Weitere Suchoptionen
307 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Abgeschlossene Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EASE SBS 2: A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
Eine doppelblinde Phase-3-Verlängerungsstudie zur Beurteilung der langfristigen Sicherheit und Wirksamkeit von Glepaglutid bei Patienten mit Kurzdarmsyndrom (SBS)
Department für Innere Medizin - Medizinische Universitätsklinik Tübingen
Innere Medizin I - Gastroenterologie, Hepatologie und Infektiologie
DEUTSCHLAND
Berlin
BERLIN
Eine doppelblinde Phase-3-Verlängerungsstudie zur Beurteilung der langfristigen Sicherheit und Wirksamkeit von Glepaglutid bei Patienten mit Kurzdarmsyndrom (SBS)
Charité - Universitätsmedizin Berlin
DEUTSCHLAND
Mecklenburg-Vorpommern
ROSTOCK
Eine doppelblinde Phase-3-Verlängerungsstudie zur Beurteilung der langfristigen Sicherheit und Wirksamkeit von Glepaglutid bei Patienten mit Kurzdarmsyndrom (SBS)
Universitätsmedizin Rostock
FRANKREICH
ILE-DE-FRANCE
PARIS
REVE : A Monocentric Single-arm Study to Characterize the Long-term Safety, Efficacy, and Pharmacodynamic of GLP-2 Analog (Revestive®) in the Management of Short Bowel Syndrome Pediatric Patients on Home-parenteral Nutrition (HPN) (Phase IV)
Hôpital Necker-Enfants Malades
Service de gastro-entérologie, hépatologie et nutrition pédiatriques
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer - IT
Institution: Information not provided - IT
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
Alternative therapy using continuous intravenous administration of adrenomedullin for patients with inflammatory bowel disease
Institution: Information not provided - JP
NIEDERLANDE
Noord-Holland
AMSTERDAM
Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer
Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
Afdeling Medische Oncologie
SCHWEIZ
Suisse Romande
GENÈVE
Nab-PIPAC - A Phase 1b Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity
Hôpitaux Universitaires de Genève HUG
Service d'Oncologie
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
BOUQUET: A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors -ES
Institution: Information not provided - ES
VEREINIGTES KONIGREICH
Greater London
LONDON
EASE SBS 2: A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)GB
Joint UCLH/UCL Biomedical Research and Development (R&D) Unit
University College London (UCL) and University College London Hospitals NHS Trust (UCLH)
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - BE
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PRECISION 2: Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination (HR) Genes, a Belgian Precision phase II basket study
Universitair Ziekenhuis Brussel
Oncologisch centrum
BELGIEN
VLAAMS BRABANT
LEUVEN
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Platinum-resistant Ovarian Cancer (PROC) - BE
UZ Leuven - Campus Gasthuisberg
Gynaecological Oncology laboratory
BELGIEN
VLAAMS BRABANT
LEUVEN
A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal alpha-emitting Radionuclide Therapy (Radspherin®) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following Complete Surgical Resection - BE
UZ Leuven - Campus Gasthuisberg
Gynaecological Oncology laboratory
BELGIEN
VLAAMS BRABANT
LEUVEN
ATHENA: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy - BE
UZ Leuven - Campus Gasthuisberg
Gynaecological Oncology laboratory
BELGIEN
VLAAMS BRABANT
LEUVEN
A prospective, randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer- BE
UZ Leuven - Campus Gasthuisberg
Dienst Gynaecologie en Verloskunde / Clinical Department of Obstetrics and Gynaecology
BELGIEN
VLAAMS BRABANT
LEUVEN
CINOVA: A Phase IIa Exploratory 2-stage Design Study of CPC634 (CriPec® Docetaxel) Monotherapy in Subjects With Platinum Resistant Ovarian Cancer - BE
UZ Leuven - Campus Gasthuisberg
Dienst Gynaecologie en Verloskunde / Clinical Department of Obstetrics and Gynaecology
BELGIEN
VLAAMS BRABANT
LEUVEN
STARS: Etude multicentrique en double aveugle, randomisée, contrôlée, par placebo visant à évaluer l'efficacité et la sécurité de l'apraglutide chez des patients adultes présentant un syndrome du grêle court avec une insuffisance intestinale (SGC-II) - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
BELGIEN
VLAAMS BRABANT
LEUVEN
STARS extend: An Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
BELGIEN
VLAAMS BRABANT
LEUVEN
STARSnutrition: A Multicenter, Open-label, Metabolic Balance Study to Evaluate the Effects of Apraglutide on Intestinal Absorption in Adult Subjects With Short Bowel Syndrome, Intestinal Failure (SBS-IF), and Colon-in-Continuity (CIC) - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
BELGIEN
VLAAMS BRABANT
LEUVEN
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy - BE
UZ Leuven - Campus Gasthuisberg
General medical oncology/Dienst Algemene Medische Oncologie
BELGIEN
VLAAMS BRABANT
LEUVEN
DUO-O: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients - BE
UZ Leuven - Campus Gasthuisberg
General medical oncology/Dienst Algemene Medische Oncologie
BELGIEN
VLAAMS BRABANT
LEUVEN
A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma - BE
UZ Leuven - Campus Gasthuisberg
Pneumology department
DEUTSCHLAND
Bayern
MÜNCHEN
DUO-O: Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische Phase III Studie mit Durvalumab (MEDI4736) in Kombination mit Chemotherapie und Bevacizumab, gefolgt von einer Erhaltungstherapie mit Durvalumab, Bevacizumab und Olaparib bei Patientinnen mit neu diagnostiziertem fortgeschrittenem Ovarialkarzinom
LMU Klinikum der Universität München - Campus Großhadern
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
AGO-OVAR 2.29: Atezolizumab in Kombination mit Bevacizumab und Chemotherapie versus Bevacizumab und Chemotherapie bei rezidivierendem Eierstockkrebs - eine randomisierte Phase-III-Studie - DE
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
PAOLA-1: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment - DE
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase-2-Studie zur Beurteilung der Wirksamkeit und Sicherheit von Farletuzumab (MORAb 003) in Kombination mit Carboplatin plus Paclitaxel oder Carboplatin plus pegyliertem Liposomal-Doxorubicin (PLD) bei Patienten mit schwachem CA125 platinempfindlichem Eierstockkrebs. - DE
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine prospektive, randomisierte klinische Prüfung der Phase III von Carboplatin/Gemcitabin/Bevacizumab vs. Carboplatin/pegyliertes liposomales Doxorubicin/Bevacizumab bei Patientinnen mit platin-sensitivem rezidivierendem Ovarialkarzinom
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische Phase-3-Studie zur Niraparib-Erhaltungstherapie bei Patienten mit fortgeschrittenem Eierstockkrebs nach Ansprechen auf eine Front-Line Platinbasierte Chemotherapie
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine einarmige, offene, multizentrische Phase-II-Studie zur Bewertung der Wirksamkeit und Sicherheit der Pembrolizumab-Monotherapie bei Patienten mit fortgeschrittenem wiederkehrenden Eierstockkrebs
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
ATHENA: Eine multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Phase-3-Studie zur Evaluation von Rucaparib und Nivolumab als Erhaltungstherapie bei Eierstockkrebspatienten, nach Ansprechen auf eine platinbasierte Erstlinien-Chemotherapie.
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine randomisierte Phase-3-Doppelblindstudie mit zwei Setmelanotid-Formulierungen (täglich und wöchentlich) mit einem Crossover zu einmal wöchentlichem Setmelanotid mit offener Zulassung bei Patienten mit spezifischen Gendefekten im Melanocortin-4-Rezeptor-Signalweg, die derzeit eine stabile Dosis der einmal täglichen Formulierung erhalten
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
BERLIN
Eine multizentrische, offene Phase-II-Studie mit einer neuen maßgeschneiderten Dosierung (RADAR-Dosierung) von Niraparib als Erhaltungstherapie bei platinempfindlichen Eierstock-, Eileiter- oder primären Peritonealkrebspatienten
Charité - Universitätsmedizin Berlin
DEUTSCHLAND
Berlin
BERLIN
NOGGO ov42 - MAMOC: Rucaparib-Erhaltung nach Bevacizumab-Erhaltung nach Carboplatin-basierter Erstlinien-Chemotherapie bei Patientinnen mit Eierstockkrebs
Charité - Universitätsmedizin Berlin (CVK)
Klinik für Gynäkologie mit Zentrum für onkologische Chirurgie (CVK)
DEUTSCHLAND
Hamburg
HAMBURG
Trabectedin/PLD versus Fortsetzung der Platin-basierten Chemo-Therapie bei Patienten mit Krankheitsstabilisierung und ohne Symptomvorteil unter Platin-basierter Chemotherapie bei rezidivierendem Eierstockkrebs
Krankenhaus Jerusalem
Mammazentrum Hamburg MVZ GbR
DEUTSCHLAND
Hamburg
HAMBURG SCHNELSEN
DUO-O: Eine randomisierte, doppelblinde, Placebo-kontrollierte, multizentrische Phase III Studie mit Durvalumab (MEDI4736) in Kombination mit Chemotherapie und Bevacizumab, gefolgt von einer Erhaltungstherapie mit Durvalumab, Bevacizumab und Olaparib bei Patientinnen mit neu diagnostiziertem fortgeschrittenem Ovarialkarzinom
Albertinen Krankenhaus
Tumorzentrum Albertinen Krankenhaus
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
OlaReDo: Wirksamkeit von Olaratumab und Wiederauftreten mit Doxorubicin bei Anthrazyklin vorbehandelten, fortgeschrittenen Weichteilsarkompatienten. Eine explorative Phase-II-Studie
Krankenhaus Nordwest GmbH
Institut für Klinische Krebsforschung IKF GmbH
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
Phase I/II G1XCGD.01 Sudie: Nicht randomisierte, multizentrische, offene Phase I/II-Gentherapiestudie mit g1xcgd (Lentiviral Vector Transduced cd34+ Cells) zur Behandlung der X-chromosomalen chronischen Granulomatose
Universitätsklinikum Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
DEUTSCHLAND
Hessen
FRANKFURT AM MAIN
BOOST-Studie: Eine prospektive randomisierte Phase III Studie zur Evaluierung der optimalen Therapiedauer von Bevacizumab in Kombination mit Paclitaxel und Carboplatin bei Patientinnen mit primärem epithelialem Ovarial-, Tuben- oder Peritonealkarzinom -DE-
Universitätsklinikum Frankfurt
Medizinische Klinik II - Hämatologie, Onkologie, Hämostaseologie, Rheumatologie, Infektiologie
DEUTSCHLAND
Nordrhein-Westfalen
DÜSSELDORF
Eine randomisierte, doppelblinde Phase-III-Studie mit Atezolizumab versus Placebo bei Patienten mit spätem Rückfall von epithelialem Eierstock-, Eileiter- oder Peritonealkrebs, die durch platinbasierte Chemotherapie und Bevacizumab behandelt werden.
Universitätsklinikum Düsseldorf
Frauenklinik
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
Eine multizentrische, offene Phase-II-Studie mit einer neuen maßgeschneiderten Dosierung (RADAR-Dosierung) von Niraparib als Erhaltungstherapie bei platinempfindlichen Eierstock-, Eileiter- oder primären Peritonealkrebspatienten
Evang. Kliniken Essen-Mitte gGmbH
DEUTSCHLAND
Sachsen
DRESDEN
Eine multizentrische, offene Phase-II-Studie mit einer neuen maßgeschneiderten Dosierung (RADAR-Dosierung) von Niraparib als Erhaltungstherapie bei platinempfindlichen Eierstock-, Eileiter- oder primären Peritonealkrebspatienten
Universitätsklinikum Carl Gustav Carus an der TU Dresden
Universitätsklinikum Dresden
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
PAOLA-1: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo in Patients With Advanced FIGO Stage IIIB-IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment- FR
CLCC Léon Bérard
Cancérologie médicale - Gynécologie médicale, Tumeurs rares de l'ovaire
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
Hospices Civils de Lyon
FRANKREICH
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
EWOC-1 : Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer (Phase II) - FR
CHU de Lyon HCL - GH Sud
Service de médecine du vieillissement - soins de suite et de rééducation et réadaptation
FRANKREICH
GRAND-EST
STRASBOURG
ATALANTE : A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - FR
CHU de Strasbourg - Hôpital de Hautepierre
Pôle d'Onco-hématologie
FRANKREICH
GRAND-EST
STRASBOURG
A prospective, randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer - FR
CHU de Strasbourg - Hôpital de Hautepierre
Pôle d'Onco-hématologie
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase I study of S 78454 given with a fixed dose infusion of pegylated liposomal doxorubicin in the treatment of primary epithelial ovarian, fallopian tube or primary peritoneal carcinoma (Phase I) - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
ANITA: A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
CHIPPI: Phase III Randomized Clinical Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer Considering Two Different Settings: Primary Debulking Surgery (PDS) and Interval Debulking Surgery (IDS)
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -FR
Institution: Information not provided - FR
FRANKREICH
ILE-DE-FRANCE
BOBIGNY
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
CHU Paris Seine-Saint-Denis - Hôpital Avicenne
FRANKREICH
ILE-DE-FRANCE
PARIS
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP) - FR
AP-HP.Sorbonne Université - Hôpital Saint-Antoine
CHU Paris Est - Hôpital Saint-Antoine
FRANKREICH
ILE-DE-FRANCE
PARIS
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients - FR
CHU Paris Centre - Hôpital Hôtel-Dieu
Service d'Oncologie Médicale
FRANKREICH
ILE-DE-FRANCE
PARIS
A Phase I/II, Non Randomized, Monocentric Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-Linked Chronic Granulomatous Disease
Hôpital Necker-Enfants Malades
Service d'Immuno-hématologie pédiatrique
FRANKREICH
NORMANDIE
CAEN
TAPAZ : A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance
Centre François Baclesse
CLCC François Baclesse
FRANKREICH
NORMANDIE
CAEN
MONAVI-1 : A phase II study of ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer
Centre François Baclesse
CLCC François Baclesse
FRANKREICH
NORMANDIE
CAEN
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients - FR
Centre François Baclesse
CLCC François Baclesse
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
CIRSAR: Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
PAYS DE LA LOIRE
LE MANS
The BOOST Trial: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer - FR
Centre Jean Bernard
Clinique Victor Hugo
IRLAND
County Cork
CORK
ATHENA: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy -IE
Cork University Hospital
Department of Medical Oncology
ITALIEN
CAMPANIA
NAPOLI
MITO 35a: A Multicenter, Prospective, Single Arm Trial of Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wildtype Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
S.C. Oncologia Medica Uro-Ginecologica
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
PAOLA-1: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment - IT
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
DUO-O: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients - IT
Institution: Information not provided - IT
ITALIEN
EMILIA ROMAGNA
BOLOGNA
Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma
IRCCS Policlinico Sant'Orsola
S.S.D. Oncologia Medica
ITALIEN
LAZIO
ROMA
The NUVOLA TRIAL: Neoadjuvant Chemotherapy in Unresectable oVarian Cancer With OLAparib and Weekly Carboplatin Plus Paclitaxel: A Phase II Open-label Multicentre Study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
U.O.C. Ginecologia Oncologica
ITALIEN
LOMBARDIA
MILANO
The BAROCCO Study (Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib): an Italian Multicenter Randomized Phase II Study of Weekly Paclitaxel vs. Cediranib-Olaparib With Continuous Schedule vs. Cediranib-Olaparib With Intermittent Schedule in Patients With Platinum Resistant High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
IRCCS Istituto Europeo di Oncologia
Divisione di Ginecologia Oncologica Medica
ITALIEN
MOLISE
CAMPOBASSO
Phase II-III: A multicenter trial of Abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapy - IT
Università Cattolica di Campobasso
Centro di Ricerca e Formazione ad Alta tecnologia nelle Scienze Biomediche
JAPAN
JAPAN
ADDRESS : NOT PROVIDED - JP
Double-blind placebo-controlled clinical trial of thalidomide for chronic granulomatous disease-associated colitis
Institution: Information not provided - JP
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
KEYNOTE-100: A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer-CA
Institution: Information not provided - CA
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
OPINION: A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy-CA
Institution: Information not provided - CA
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
ATHENA: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy-CA
Institution: Information not provided - CA
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - CA
NORWEGEN
Østlandet
OSLO
A phase 1 study to Evaluate the Dose, Safety and Tolerability of an interaperitoneal a-emitting Radionuclide Therapy (Radspherin) in Patients With Platinum Sensitive Reccurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinomatosis Following Complete Surgical Resection
Oslo University Hospital, Radiumhospitalet
Department of Oncolocy, Oslo University Hospital, Radiumhospitalet
OSTERREICH
TIROL
INNSBRUCK
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Platinum-resistant Ovarian Cancer (PROC) - AT
Medizinische Universität Innsbruck
Universitätsklinik für Gynäkologie und Geburtshilfe
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
OPINION: A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
DUO-O: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
HIPEC-OVAR-REZIDIV-2014-1.1: Feasibility of a Unique Intraoperatively Given Hyperthermal Intraperitoneal Chemotherapy With Carboplatin During a Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma (Phase 2) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer - a randomized Phase III trial - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
EPIK-O: A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicenter, Long-term Treatment Extension Study in Subjects Who Have Completed a Prior GlaxoSmithKline/TESARO-Sponsored Niraparib Study and Are Judged by the Investigator to Benefit From Continued Treatment With Niraparib (Phase 2) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
MATAO: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study) - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
Phase 2 Study to Evaluate the Safety & Efficacy of EP0057 in Combination With Olaparib in Advanced Ovarian Cancer Patients Who Have: Cohort 1 - Platinum Resistant Disease; Cohort 2 - Had at Least 1 Prior Line of Therapy Which Must Include at Least 1 Line of Platinum-based Chemotherapy Followed by PARP Inhibitor Maintenance - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
FORTITUDE-301: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression - AT
Institution: Information not provided - AT
POLEN
Gdansk
GDANSK
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen - PL
Uniwersyteckie Centrum Kliniczne
Department of oncology and radiotherapy
SCHWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma - SE
Institution: Information not provided - SE
SCHWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
A randomized, double blind, parallel-group, dose escalation placebo-controlled multicentre study to investigate the safety and tolerability of IBP-9414 administered in preterm infants - SE
Institution: Information not provided - SE
SCHWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
PAOLA-1: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment - SE
Institution: Information not provided - SE
SCHWEDEN
Region Stockholm
SÖDERTALJE
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
ANNOUNCE 2: A Phase 1b (Open-Label) / Phase 2 (Randomized,Double-Blinded) Study Evaluating Gemcitabine andDocetaxel With or Without Olaratumab in the Treatment ofAdvanced Soft Tissue Sarcoma -GB
Institution: Information not provided - CH
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP) -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
ATALANTE: A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
ATHENA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
KEYNOTE-158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
DUO-O: A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
The Connection study: A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
CAMPFIRE: A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
STARS: Etude multicentrique en double aveugle, randomisée, contrôlée, par placebo visant à évaluer l'efficacité et la sécurité de l'apraglutide chez des patients adultes présentant un syndrome du grêle court avec une insuffisance intestinale (SGC-II) -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Velusetrag for the treatment of Chronic Intestinal Pseudo-Obstruction (CIPO). A multicenter double-blind, placebo-controlled, cross-over, multiple (n=1) trial -ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants With Familial Adenomatous Polyposis - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
STARS extend: An open-label extension trial to evaluate the long-term safety of apraglutide in short bowel syndrome - ES
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
A Phase 3 Multi-Center, One-Year, Open-Label study of Setmelanotide in Pediatric Patients Aged 2 to <6 years of age with Rare Genetic Causes of Obesity -ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (msb0010718c) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Multicenter, Randomized, Open-label Study Of Avelumab (msb0010718c) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Phase IB Study of Weekly Paclitaxel + Carboplatin With the BMI-1 Inhibitor PTC596 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Hyperthermic Intraperitoneal Chemotherapy or Intraperitoneal Chemotherapy in Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (suspended)
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Aberdeenshire
ABERDEEN
OPINION: A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy-GB
NHS Grampion
Department of Medical Oncology
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Institution: Information not provided - GB
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB
CeNturIOn :An open-label, randomised, phase I/II trial of ruCaparib combined with Nivolumab +/- Ipilimumab to augment response in homologous repair deficient patients with relapsed Ovarian, primary peritoneal and fallopian tube cancer -GB
Institution: Information not provided - GB
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -CA
Institution: Information not provided - GB
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation -GB
Institution: Information not provided - GB
VEREINIGTES KONIGREICH
Greater London
LONDON
ICON9:International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy -GB
Cancer Research UK & UCL Cancer Trials Centre
VEREINIGTES KONIGREICH
Greater London
LONDON
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
Great Ormond Street Hospital
Molecular and Cellular Immunology Unit
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A phase Ib/II open-label, multi-center study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumors - UK
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
OCTOVA: Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA) - GB
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma - GB
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Greater Manchester
MANCHESTER
MOLTO:Single arm feasibility of multi-maintenance olaparib after disease recurrence in participants with platinum sensitive BRCAm high grade serous ovarian cancer -GB
The Christie, NHS Foundation Trust
The Christie NHS Foundation Trust
VEREINIGTES KONIGREICH
Kent
MAIDSTONE
ATHENA: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy-GB
Maidstone Hospital
Kent Oncology Centre
VEREINIGTES KONIGREICH
West Midlands
BIRMINGHAM
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic
BELGIEN
NAMUR
YVOIR
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma - BE
Cliniques Universitaires UCL de Mont-Godinne
Department of Hematology
BELGIEN
OOST-VLAANDEREN
GENT
Phase II Study Comparing Normothermic Versus Hyperthermic Intraoperative Chemoperfusion With Oxaliplatin in Patients With Peritoneal Metastases From Appendiceal or Colon Cancer - BE
Ghent University Hospital - UZ Gent
Department of Gastrointestinal Surgery
CHINA
CHINA
ADDRESS: NOT PROVIDED - CN
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Institution: Information not provided - CN
DEUTSCHLAND
Baden-Württemberg
FREIBURG
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
CCI am Universitätsklinikum Freiburg
Centrum für Chronische Immundefizienz
DEUTSCHLAND
Baden-Württemberg
HEIDELBERG
CHARLY: Eine Studie zum Stellenwert von Cyclophosphamid nach Thiotepa-Basierter Haplo-identer Stammzelltransplantation für refraktäre non-Hodgkin Lymphome
Zentrum für Innere Medizin (Krehl-Klinik)
Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie
DEUTSCHLAND
Bayern
MÜNCHEN
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
Medizinische Klinik und Poliklinik IV - Standort Ziemssenstraße
Medizinische Klinik und Poliklinik IV
DEUTSCHLAND
Schleswig-Holstein
KIEL
ABACHAI: Sicherheit und Wirksamkeit von Abatacept (s.c.) bei Patienten mit CTLA4-Insuffizienz oder LRBA-Defizienz (Studie des GAIN-Netzwerks)
Universitätsklinikum Schleswig-Holstein - Campus Kiel
Klinik für Innere Medizin I
FRANKREICH
AUVERGNE-RHONE-ALPES
PIERRE-BENITE
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma - FR
CHU de Lyon HCL - GH Sud
Service d'hématologie clinique
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3601, a synthetic parathyroid hormone analog, in healthy subjects and in subjects with hypoparathyroidism - FR
Institution: Information not provided - FR
FRANKREICH
ILE-DE-FRANCE
PARIS
ACTHYF: Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children - FR
Institut Jérôme Lejeune
ITALIEN
LOMBARDIA
MILANO
A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial
Fondazione IRCCS Istituto Nazionale dei Tumori
S.S. Oncologia Medica Gastroenterologica
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
Phase III Clinical Trial for CPX-351 in Myeloid Leukemia in Children with Down Syndrome 2018 - AT
Institution: Information not provided - AT
PORTUGAL
NORTE
PORTO
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Instituto Português de Oncologia do Porto Francisco Gentil, EPE
Serviço de Onco-Hematologia
PORTUGAL
SUL
LISBOA
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Centro Hospitalar Universitário Lisboa Norte, EPE - Hospital de Santa Maria
Serviço de Hematologia e Transplantação de Medula
PORTUGAL
SUL
LISBOA
A Randomized Phase III Study to Evaluate the Efficacy of Chemoimmunotherapy With the Monoclonal Antibody Campath-1H (Alemtuzumab) Given in Combination With 2-weekly CHOP Versus 2-weekly CHOP Alone and Consolidated by Autologous Stem Cell Transplant, in Young Patients With Previously Untreated Systemic Peripheral T-cell Lymphomas (Phase III)
Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE
Departamento de Hematologia
SPANIEN
Cataluña
L'HOSPITALET DE LLOBREGAT
CheckMate 436: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Hematología Clínica
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
AVAIL-T: A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma
Institution: Information not provided - UK
VEREINIGTES KONIGREICH
Oxfordshire
OXFORD
RomiCar - Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
Churchill Hospital
Department of Haematology
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy- BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Gastro-entérologie, hépatopancréatologie, endoscopie et oncologie digestive
BELGIEN
VLAAMS BRABANT
LEUVEN
INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies - BE
UZ Leuven - Campus Gasthuisberg
Dienst maag-, darm- en leverziekten (gastro-enterologie en hepatologie)
DEUTSCHLAND
Baden-Württemberg
MANNHEIM
INVICTUS: Eine Phase-3-Studie zur Beurteilung der Sicherheit und Wirksamkeit von DCC-2618 bei Patienten mit fortgeschrittenem gastrointestinalen Stromatumor, die mit früheren Krebstherapien behandelt wurden.
Universitätsmedizin Mannheim
Sarkom-Zentrum
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Eine randomisierte, doppelt-verblindete, Placebo-kontrollierte, multizentrische Studie mit Crenolanib bei Patienten mit fortgeschrittenen oder metastasierten gastrointestinalen Stromatumoren mit einer D842V-Mutation im PDGFRA-Gen (Phase III)
Institution: Information not provided - DE
DEUTSCHLAND
Brandenburg
BAD SAAROW
INVICTUS: Eine Phase-3-Studie zur Beurteilung der Sicherheit und Wirksamkeit von DCC-2618 bei Patienten mit fortgeschrittenem gastrointestinalen Stromatumor, die mit früheren Krebstherapien behandelt wurden.
HELIOS Klinikum Bad Saarow
Sarkomzentrum Berlin-Brandenburg
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
POETIG: Phase 2-Studie mit Ponatinib bei Patienten mit metastatischem und / oder inoperablem gastrointestinalen Stroma-Tumor (GIST) nach Versagen oder Intoleranz einer früheren Therapie mit Imatinib
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Innere Medizin (Tumorforschung)
DEUTSCHLAND
Nordrhein-Westfalen
ESSEN
INVICTUS: Eine Phase-3-Studie zur Beurteilung der Sicherheit und Wirksamkeit von DCC-2618 bei Patienten mit fortgeschrittenem gastrointestinalen Stromatumor, die mit früheren Krebstherapien behandelt wurden.
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Innere Medizin (Tumorforschung)
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
NAVIGATOR: A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors - FR
CLCC Léon Bérard
Cancérologie médicale - Gynécologie médicale, Tumeurs rares de l'ovaire
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
ImadGist : A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
CLCC Léon Bérard
Cancérologie médicale - Sarcomes et GIST, Tumeurs rares
FRANKREICH
AUVERGNE-RHONE-ALPES
LYON
GIST-TEN: Randomized, Multicentre, Phase II Study Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After at Least 10 Years of Treatment in Patients With Locally Advanced/Metastatic Gastrointestinal Stromal Tumors (GISTs) -FR
CLCC Léon Bérard
Centre Léon Bérard
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
GRID: A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib - FR
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for p
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
LILLE
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmen - FR
CLCC Oscar Lambret
Département de cancérologie générale
FRANKREICH
HAUTS-DE-FRANCE
LILLE
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment - BE
CLCC Oscar Lambret
Département de cancérologie générale
FRANKREICH
ILE-DE-FRANCE
PARIS
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy - FR
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière
Service d'oncologie médicale
FRANKREICH
ILE-DE-FRANCE
VILLEJUIF
Phase II Study of Oral AB1010 (Masitinib) in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
CLCC Institut Gustave Roussy
Département de Médecine oncologique - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
CYCLIGIST: Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
BORDEAUX
ALT GIST: A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) - FR
CLCC Institut Bergonié
Département d'oncologie médicale - Sarcomes
FRANKREICH
NOUVELLE AQUITAINE
PESSAC
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment - FR
CHU de Bordeaux-GH Sud - Hôpital Haut-Lévêque
Service d'hématologie et thérapie cellulaire
ITALIEN
PUGLIA
SAN GIOVANNI ROTONDO
Randomized study in open at active control of IIIb phase, of Sunitinib vs Imatinib in the treatment of patients with metastasized gastrointestinal tumor whose disease is evolved under treatment of Imatinib
Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza
U.O. di Oncologia
KANADA
Québec
ADDRESS: NOT PROVIDED - CA
INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal Tumors who have Received Treatment with Prior Anticancer Therapies-CA
Institution: Information not provided - CA
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Prospective, Multicenter, Randomized, Open-label, Active-controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients With Gastrointestinal Stromal Tumor After Progression With Imatinib at 400mg as First Line Treatment - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
An Open Label, Randomized Phase II Study of BI 754091 Alone or in Combination With BI 836880 in Patients With Chemotherapy Resistant, Unresectable, Metastatic Squamous Cell Carcinoma of the Anal Canal - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling - AT
Institution: Information not provided - AT
OSTERREICH
WIEN
WIEN
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
OSTERREICH
WIEN
WIEN
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
OSTERREICH
WIEN
WIEN
An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
OSTERREICH
WIEN
WIEN
VOYAGER: An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Onkologie
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene (Phase III) - CH
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment - CH
Institution: Information not provided - CH
SPANIEN
Cataluña
BADALONA
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Oncología Médica
SPANIEN
Cataluña
BARCELONA
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene -ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPANIEN
Cataluña
BARCELONA
SeliGIST: A multicenter, phase Ib/II trial of selinexor in combination with imatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GISTs) - ES
Hospital Universitari Vall d'Hebron
Servicio de Oncología Médica
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
Intrigue: A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib - ES
Institution: Information not provided - ES
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
POD1UM-303/InterAACT 2: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy - ES
Institution: Information not provided - ES
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene. -GB
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Cambridgeshire
CAMBRIDGE
CAMN107A2409: An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - UK
Addenbrooke's Hospital
Addenbrookes Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
CAMN107A2409: An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV) - UK
Royal Marsden Hospital
Section of Medicine
VEREINIGTES KONIGREICH
Greater London
SURREY
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy -GB
The Royal Marsden
Royal Marsden NHS Foundation Trust
VEREINIGTES KONIGREICH
Greater Manchester
ADDRESS: NOT PROVIDED - UK
A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Institution: Information not provided - UK
FRANKREICH
BOURGOGNE-FRANCHE-COMTE
DIJON
BALLAD : Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma - FR
CHU Dijon Bourgogne - Hôpital François Mitterrand
Service d'hépato-gastroentérologie
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Glasgow
GLASGOW
A trial to evaluate the potential benefit of adjuvant chemotherapy for small bowel adenocarcinoma - GB
Beatson West of Scotland Cancer Centre
VEREINIGTES KONIGREICH
Greater London
LONDON
A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours - UK
St Bartholomew's Hospital, Barts and The London NHS Trust
Centre for Endocrinology
Multinationale klinische Studie(n)
DANEMARK
Sjælland
GLOSTRUP
EASE SBS 2: A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients With Short Bowel Syndrome (SBS)
Zealand Pharma A/S
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer
Institution: Information not provided - CH
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Institution: Information not provided - US
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma (Coordination)
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma
Institution: Information not provided - BE
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
ANITA: A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease
Institution: Information not provided - BE
BELGIEN
VLAAMS BRABANT
LEUVEN
ENGOT-ov50 / GOG-3029 / INNOVATE-3: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant With Weekly Paclitaxel for the Treatment of Platinum-resistant Ovarian Cancer (PROC)
UZ Leuven - Campus Gasthuisberg
Leuven Cancer Institute
BELGIEN
VLAAMS BRABANT
LEUVEN
EUDARIO: A Multicentre, Open-label, Three-arm Randomised Phase II Trial Assessing the Safety and Efficacy of the HSP90 Inhibitor Ganetespib in Combination With Carboplatin Followed by Maintenance Treatment With Niraparib Versus Ganetespib Plus Carboplatin Followed by Ganetespib and Niraparib Versus Carboplatin [...] in Platinum-sensitive Ovarian Cancer Patients
UZ Leuven - Campus Gasthuisberg
UZ Leuven
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
The BOOST Trial: A prospective randomised Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)
Institution: Information not provided - DE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
PazoQol: Quality of life in patients with non-adipocyte soft tissue sarcoma underpalliative chemotherapy or pazopanib - a randomized, controlled trial
Institution: Information not provided - DE
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
PAOLA-1: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment
Institution: Information not provided - FR
FRANKREICH
ILE-DE-FRANCE
EVRY
NET4CGD: Gene Therapy for X-linked Chronic Granulomatous Disease (CGD)
Généthon
Centre de Recherche Généthon
IRLAND
County Dublin
ADDRESS: NOT PROVIDED - IE
A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support
Institution: Information not provided - IE
ITALIEN
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM)
Institution: Information not provided - IT
ITALIEN
LAZIO
POMEZIA
Phase II-III: A multicenter trial of abagovomab maintenance therapy in patients with epithelial ovarian cancer after complete response to first line chemotherapy (MIMOSA) (coordination)
Menarini Ricerche S.p.A.
ITALIEN
LOMBARDIA
MILANO
Newton: A Multicenter, Open-label Phase II Trial of a New Customized Dosing (RADAR Dosing) of Niraparib as Maintenance Therapy in Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Recurrent Cancer Patients
IRCCS Istituto Europeo di Oncologia
ITALIEN
LOMBARDIA
MILANO
INOVATYON: Phase III International, Randomized Study of Trabectedin Plus Pegylated Liposomal Doxorubicin (PLD) Versus Carboplatin Plus PLD in Patients With Ovarian Cancer Progressing Within 6-12 Months of Last Platinum
Istituto di Ricerche Farmacologiche Mario Negri
NIEDERLANDE
Utrecht
ADDRESS: NOT PROVIDED - NL
CINOVA: A Phase Ila Exploratory 2-stage Design Study of CPC634 (CriPec® Docetaxel) Monotherapy in Subjects With Platinum Resistant Ovarian Cancer.
Institution: Information not provided - NL
NORWEGEN
Østlandet
ADDRESS: NOT PROVIDED - NO
A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal a-emitting Radionuclide Therapy (Radspherin®) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following Complete Surgical Resection
Institution: Information not provided - NO
SCHWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
OPINION: A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy
Institution: Information not provided - SE
SCHWEDEN
Region Stockholm
STOCKHOLM
The Connection Study: A Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IBP-9414 in Premature Infants 500-1500g Birth Weight in the Prevention of Necrotizing Enterocolitis
Infant Bacterial Therapeutics AB
SCHWEDEN
Region Stockholm
SÖDERTALJE
SCHWEIZ
Suisse Alémanique
BASEL
IMagyn050: A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SCHWEIZ
Suisse Alémanique
BASEL
Open Label, Dose Finding and Expansion Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Hoffmann-La Roche
Hoffmann - La Roche Ltd.
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
PENELOPE: A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer.
Institution: Information not provided - CH
SPANIEN
Cataluña
SANT QUINTÍ DE MEDIONA
VEREINIGTE STAATEN
California
PLEASANTON
A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer
Astex Pharmaceuticals, Inc
VEREINIGTE STAATEN
Colorado
BOULDER
VEREINIGTE STAATEN
New Jersey
RAHWAY
KEYNOTE 158: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors
Merck, Sharp & Dohme Corp.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
PROCEED: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A long term, open label study with Teduglutide for subjects with parenteral nutrition-dependent short bowel syndrome (Phase III)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA).
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Phase I study of oral administration of S 78454 given with a fixed dose infusion of pegylated liposomal doxorubicin in the treatment of primary platinum-resistant and partially platinum-sensitive, epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer.
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A prospective, randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38MAPK Inhibitor, plus Gemcitabine and Carboplatin versus Gemcitabine and Carboplatin for Women with Platinum-Sensitive Ovarian Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
TRINOVA-2: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
TRINOVA-1: A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
ATALANTE: A randomized, double-blinded, phase III study of atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and bevacizumab
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
ATHENA: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
KEYNOTE-100: A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects with Advanced Recurrent Ovarian Cancer
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Maralixibat in the Treatment of Subjects With Biliary Atresia After Hepatoportoenterostomy
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Double-Blind Trial of Two Formulations of Setmelanotide (Daily and Weekly) With a Crossover to Open-Label Once Weekly Setmelanotide in Patients With Specific Gene Defects in the Melanocortin-4 Receptor Pathway Who Are Currently on a Stable Dose of the Once Daily Formulation.
Institution: Information not provided - US
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB
A phase III study to evaluate the efficacy and safety of Pazopanib Monotherapy versus Placebo in women who have not progressed after first line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (coordination)
Institution: Information not provided - GB
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB
EPA-Pol-04: Randomised, double-blind, placebo-controlled study of the, efficacy, safety and tolerability of EPA-FFA gastro-resistant capsules, in patients with familial adenomatous polyposis (FAP).
Institution: Information not provided - GB
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
Phase 3 multi-center randomized study to compare efficacy and safety of romidepsin-CHOP (Ro-CHOP) versus CHOP in patients with previously untreated peripheral T-cell lymphoma
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
SONNET: Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study
Institution: Information not provided - FR
FRANKREICH
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3601, a synthetic parathyroid hormone analog, in healthy subjects and in subjects with hypoparathyroidism
Institution: Information not provided - FR
VEREINIGTE STAATEN
California
LOS ANGELES
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Children's Hospital Los Angeles
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (Coordination)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy (Coordination)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
Phase III Clinical Trial for the Treatment of Myeloid Leukemia in Children with Down Syndrome 2018 - ML-DS 2018
Institution: Information not provided - US
AUSTRALIEN
Victoria
ADDRESS: NOT PROVIDED - AU
ALT GIST: A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
Institution: Information not provided - AU
BELGIEN
ARRONDISSEMENT BRUSSELS-CAPITAL
ADDRESS: NOT PROVIDED - BE
Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib
Institution: Information not provided - BE
DEUTSCHLAND
Berlin
ADDRESS: NOT PROVIDED - DE
GRID: A Randomized, Double-blind, Placebo-controlled Phase III Study of Regorafenib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care for Subjects With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Whose Disease Has Progressed Despite Prior Treatment With at Least Imatinib and Sunitinib
Institution: Information not provided - DE
FRANKREICH
ILE-DE-FRANCE
PARIS
SCHWEDEN
Region Stockholm
ADDRESS: NOT PROVIDED - SE
PAGIST: Pazopanib in Advanced GISTs Refractory to Imatinib and Sunitinib - A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group
Institution: Information not provided - SE
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Single-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib (Coordination)
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
DOVIGIST: Phase II Trial to Evaluate the Efficacy and Safety of Dovitinib (TKI258) in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib (Coordination)
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib
Institution: Information not provided - CH
SCHWEIZ
Suisse Romande
ADDRESS: NOT PROVIDED - CH
An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment (Phase IV)
Institution: Information not provided - CH
SPANIEN
Madrid
ADDRESS: NOT PROVIDED - ES
REGISTRI: Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Institution: Information not provided - ES
SPANIEN
Madrid
MADRID
Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST - REGISTRI
GEIS - Grupo Español de Investigación de Sarcomas
VEREINIGTE STAATEN
Delaware
WILMINGTON
PODIUM 202: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy
Incyte Corporation
VEREINIGTE STAATEN
Kansas
LAWRENCE
A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC.
VEREINIGTE STAATEN
Massachusetts
CAMBRIDGE
NAVIGATOR: A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
VEREINIGTE STAATEN
Texas
DALLAS
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Trial of Crenolanib in Subjects with Advanced or Metastatic Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene.
Arog Pharmaceuticals, Inc.
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1/2, Multi-Center, Open-Label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the mTOR Kinase Inhibitor CC-223 Administered Orally to Subjects With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma (Coordination)
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment
Institution: Information not provided - US
VEREINIGTE STAATEN
Washington
ADDRESS: NOT PROVIDED - US
INVICTUS: A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients with AdvanCed Gastrointestinal Stromal TUmorS who have Received Treatment with Prior Anticancer Therapies
Institution: Information not provided - US
FRANKREICH
AUVERGNE-RHONE-ALPES
SAINT-GENIS-POUILLY
A multi-centre, stratified, open, randomized, comparator-controlled, parallel-group phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours
Advanced Accelerator Applications SA
Advanced Accelerator Applications
VEREINIGTES KONIGREICH
Greater London
ADDRESS: NOT PROVIDED - GB